ABCL AbCellera Biologics Inc.
Price Chart
Executive Summary
Leerink Partners downgraded ABCL from Outperform to Market Perform with a new $4 price target, marking a 57% reduction from prior levels. The firm has a 49% accuracy rate (127 of 257 calls correct), below average versus peers. Three firms have acted recently: Jones Trading initiated Buy at $11, Benchmark reiterated Hold, and Leerink downgraded. Consensus is fragmented with 1 upgrade and no downgrades in the last 90 days. Institutional activity shows divergence: Morgan Stanley and Bank of America more than doubled positions, while Renaissance and UBS trimmed significantly. Short interest remains elevated at 60.3% short ratio. Insider buys totaling $276K in February signal confidence. No earnings date is scheduled within 30 days.
Impact Score
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-04-10 | Jones Trading | initiate | Buy | $11.00 |
| 2025-11-07 | Leerink Partners | downgrade | Market Perform | $4.00 |
| 2025-08-08 | Stifel | maintain | Buy | $7.00 |
| 2025-07-14 | Keybanc | maintain | Overweight | $10.00 |
| 2025-05-16 | Truist Securities | maintain | Buy | $10.00 |
| 2025-05-09 | Stifel | maintain | Buy | $8.00 |
| 2025-04-16 | Keybanc | maintain | Overweight | $5.00 |
| 2025-03-03 | Benchmark | reiterate | Hold | — |
| 2025-02-28 | Stifel | maintain | Buy | $10.00 |
| 2025-01-08 | Keybanc | maintain | Overweight | $4.00 |
In the past 30 days, there has been 1 upgrade (Jones Trading initiate Buy) and 0 downgrades. Over the longer term, analyst momentum is mixed: 1 new Buy initiation, 1 downgrade, and 5 maintains in the last 12 months. No EPS revisions are available, limiting visibility into earnings momentum.
Firm Track Record — Leerink Partners
Leerink Partners accuracy: 49% on 257 calls | avg return: 4.3%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 3 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| Stifel | 50% | 2/4 | 26.1% | below average |
| Keybanc | 40% | 2/5 | 4.2% | below average |
| Benchmark | 33% | 1/3 | 8.3% | below average |
Leerink Partners has a 49% accuracy rate (127 of 257 calls correct) with an average return of 4.3%, below the peer average. Among firms covering ABCL, Stifel leads with 50% accuracy and 26.1% avg return, while Benchmark lags at 33% accuracy. Leerink’s track record does not outperform, reducing the weight of this downgrade.
Cross-Platform Signals
Insider activity shows bullish divergence: Thermopylae Holdings and Andrew Booth bought $276K worth in February 2026. Institutionally, Morgan Stanley and Bank of America more than doubled their stakes, while Renaissance and UBS trimmed by 28.9% and 27.8%. Short interest is extremely high at 60.3% short ratio, suggesting ongoing bearish sentiment despite buying from insiders and major banks.
Actionable Insight
Leerink’s downgrade is offset by strong institutional accumulation and insider buying — ignore this bearish signal. Favor long-side exposure with tight risk control due to extreme short interest and lack of earnings catalyst in the near term.
Documents Analyzed
Report based on filing metadata.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
7d ago
|
8-K
| $5.80 awaiting T+5 | awaiting T+5 | — | $5.24 (−9.58%) |
|
May 11, 2026
4w ago
|
8-K
| $4.95 $4.16 | ▼ −15.96% | ▼ −16.04% | $5.24 (+5.86%) |
|
Apr 21, 2026
7w ago
|
ANALYST-DOWNGRADE
| $3.99 $4.16 | ▼ −4.26% | ▼ −3.18% | $5.24 (−31.33%) |
|
Feb 27, 2026
15w ago
|
Insider Cluster
| $3.61 $3.45 | ▼ −4.43% | ▼ −2.45% | $5.24 (+45.15%) |
|
Feb 24, 2026
15w ago
|
8-K
| $3.19 $3.63 | ▲ +13.79% | ▲ +14.89% | $5.24 (+64.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access